ArticleDiagnostic pathology2026
ESM1 and protein lysine L-lactylation modification (Pan-kla) in ovarian cancer: coexpression, clinical significance, and prognostic value.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOvarian cancer (OC) remains a highly lethal gynaecologic malignancy. Endothelial cell-specific molecule 1 (ESM1) and protein lysine L-lactylation modification (Pan-kla) are key players in tumour microenvironment regulation, which involves metabolic reprogramming, angiogenesis, and immune modulation. However, their coexpression patterns, clinical relevance, and synergistic prognostic impact in OC patients have not been fully elucidated.
methodsIn this study, immunohistochemistry (IHC) was used to analyse ESM1 and Pan-kla expression in 131 ovarian cancer tissue samples from patients diagnosed between 2014 and 2024. Clinical parameters (e.g., FIGO stage, CA125 level, and ascites) and survival data were collected. Statistical analyses, including Kaplan–Meier survival and risk stratification, were performed using R software.
resultsESM1 and Pan-kla were significantly overexpressed in OC tissues, with a strong positive correlation (P < 0.0001). High expression of both biomarkers was associated with adverse clinical features: advanced FIGO stage, elevated CA125 levels, and malignant ascites. Survival analysis revealed that high ESM1 expression increased the risk of death, whereas high Pan-kla expression increased the risk. Patients exhibiting combined ESM1/Pan-kla expression were stratified into four prognostic subgroups, with the dual-high group exhibiting the worst survival (P < 0.001).
conclusionESM1 and Pan-kla synergistically promote OC progression through metabolic–epigenetic cross-regulatory mechanisms. Their combined assessment provides robust prognostic stratification and reveals potential targets for overcoming therapeutic resistance in ovarian cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.